Pharmacological properties of dolasetron, a potent and selective antagonist at 5‐HT3 receptors
- 1 January 1993
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 28 (1), 87-93
- https://doi.org/10.1002/ddr.430280111
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma × glioma cellsEuropean Journal of Pharmacology, 1992
- L‐683,877: Pharmacological profile of a novel 5‐HT3 receptor antagonistDrug Development Research, 1992
- Electrophysiology of the 5-HT1A ligand MDL 73005EF in the rat hippocampal sliceEuropean Journal of Pharmacology, 1991
- NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizationsEuropean Journal of Pharmacology, 1991
- Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron)European Journal of Pharmacology, 1989
- The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694British Journal of Cancer, 1988
- Pharmacological properties of GR38032F, a novel antagonist at 5‐HT3 receptorsBritish Journal of Pharmacology, 1988
- Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonismBritish Journal of Pharmacology, 1986
- MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptorsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1984
- Assessment of ?Ca2+-antagonist? effects of drugs in K+-depolarized smooth muscleNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1982